# A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

> **NCT02762123** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 28 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** BMS-986142 200mg
- **DRUG:** BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)
- **DRUG:** BMS-986142 350mg

## Key facts

- **NCT ID:** NCT02762123
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02762123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02762123, "A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02762123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*